Excessive angiogenesis is involved in many human diseases, and inhibiting angiogenesis is an important area of drug development. There have been conflicting reports as to whether decorin could function as an angiogenic inhibitor when used as an extracellular soluble factor. In this study, we demonstrated that not only purified decorin but also the 26-residue leucine-rich repeat 5 (LRR5) of decorin core protein functions as angiogenesis inhibitor by inhibiting both vascular endothelial growth factor (VEGF) and basic fibroblast growth factor-induced angiogenesis. Peptide LRR5 inhibited angiogenesis through multiple mechanisms, including inhibiting VEGF-stimulated endothelial cell (EC) migration, tube formation on Matrigel, cell attachment to fibronectin, as well as induction of EC apoptosis without significantly affecting their proliferation. We further demonstrated that different subregions of LRR5 inhibited different aspects of angiogenesis, with the middle region (LRR5M, 12 residues) inhibiting endothelial cell tube formation up to 1000 times more potently than LRR5. Although the C-terminal region (LRR5C) potently inhibited VEGF-stimulated endothelial cell migration, the N-terminal region (LRR5N) is as active as LRR5 in inhibiting endothelial cell attachment to fibronectin. Although both LRR5M and LRR5N induced EC apoptosis dose-dependently similar to LRR5 through a caspase-dependent pathway, LRR5C has no such function. We further showed that the inhibition of tube formation by LRR5 and LRR5M is linked with their ability to suppress VEGF-induced focal adhesion kinase phosphorylation and the assembly of focal adhesions and actin stress fibers in ECs, but not their ability to interfere with endothelial cell attachment to the matrix. Circular dichroism studies revealed that LRR5 undergoes an inter-conversion between 3 10 helix and ␤-sheet structure in solution, a characteristic potentially important for its anti-angiogenic activity. Peptide LRR5 and its derivatives are therefore novel angiogenesis inhibitors that may serve as prototypes for further development into anti-angiogenic drugs.
Proteins carry out their functions by interacting with other molecules through their functional domains. These domains vary in size, composition, and structure. In recent years, a lot of effort has been put forth to develop proteins for therapeutic applications. However, the use of proteins as drugs has limitations because of their poor bioavailability, antigenicity, unfavorable pharmacokinetics, and inconsistency in bioactivity from batch to batch productions (1) . In contrast, small peptides have the advantage of easy production by synthesis using automatic peptide synthesizers, low antigenicity, high solubility in water, and improved bioavailability with potential oral delivery (2) . Such peptides can represent complete or partial protein functional modules as well as possible protein-protein interaction sites (3) (4) (5) (6) .
Angiogenesis, the formation of new blood vessels from existing vasculature, is a multistep process involving degradation of extracellular matrix, endothelial cell proliferation and migration, capillary tube formation, and matrix remodeling (7, 8) . Many proteins are involved in this process, including growth factors and their cell surface receptors, extracellular matrix molecules, integrins, matrix metalloproteases, and their inhibitors. Several endogenous proteins such as endostatin and angiostatin, fragments of collagen and plasminogen, respectively, are potent inhibitors of angiogenesis (9, 10) . As excessive angiogenesis is involved in many human diseases, developing angiogenesis inhibitors is an important area of drug development.
Decorin, a small dermatan sulfate proteoglycan (PG), 1 is a ubiquitous component of the extracellular matrix, where it is preferentially found in association with collagen fibrils. Its major functions include regulation of collagen fibrinogenesis, maintenance of tissue integrity via binding with fibronectin and thrombospondin, and serving as a reservoir for transforming growth factor-␤ (TGF␤1) (11) (12) (13) (14) . Decorin inhibits cell adhesion and spreading on fibronectin (15) . It also inhibits the growth of various tumor cells with a diverse histogenetic background when either overexpressed in tumor cells or provided as a recombinant protein primarily via a protracted inactivation of the epidermal growth factor receptor tyrosine kinase (16, 17) . Decorin expression is induced in endothelial cells during angiogenesis, but not when migration and proliferation are stimulated. Thus, it has been hypothesized that decorin may support the formation of the fibrillar pericellular matrix that stabilizes the differentiated endothelial phenotype during the later stages of angiogenesis (18) . However, there have been conflicting reports of decorin as an angiogenesis inhibitor. Decorin was reported to suppress indirectly tumor angiogenesis through inhibition of VEGF production by tumor cells (19) . Increased expression of decorin in endothelial cells through retroviral transduction inhibited EC migration (18) . In addition, purified decorin inhibited endothelial cell migration and tube formation in collagen I lattices when ECs were grown on decorin-coated surfaces (20) . On the other hand, recombinant decorin was reported to have no effect on endothelial cell tube formation on Matrigel (19) and decorin expression in EA.hy926 ECs by adenovirus transduction-promoted tube formation in collagen lattices while inhibiting EC apoptosis (21) .
Structurally, decorin belongs to a growing family of the small leucine-rich repeat PGs. It contains a core protein of 359 amino acids linked to a single chondroitin sulfate or dermatan sulfate glycosaminoglycans (11) . The mature protein is highly conserved across species and consists of a central domain harboring 10 leucine-rich repeats (LRRs) flanked by disulfide-bonded terminal sequences. The N terminus contains a single attachment site for glycosaminoglycan, and the central domain contains three potentially N-linked glycosylation sites. LRRs are involved in protein-protein interactions and have been found in a large number of proteins, including PGs such as biglycan, fibromodulin, and lumican (22) . Decorin binds to collagen mainly through LRR4 and -5 of the core protein (23) . In addition, a high affinity binding site for TGF␤ is located between LRR3 and -5 (24) . Decorin binding to TGF␤ prevents the binding of TGF␤ to its receptor and regulates TGF␤-mediated cellular signaling (25) . Recently, it was reported that biologically active decorin is a monomer in solution, and therefore, decorin is a monovalent ligand for various extracellular matrix proteins, growth factors, and cell surface receptors (26) . However, crystal structure analysis of decorin indicated that it is a stable dimer with large interfaces (27) .
In an effort to characterize the role of decorin and its core protein LRR repeats in angiogenesis and to develop small peptide angiogenic inhibitors, we identified decorin and the 26-residue LRR5 to function as potent angiogenesis inhibitors, inhibiting VEGF, bFGF, and serum-induced angiogenesis. LRR5 inhibits angiogenesis through multiple mechanisms, including inhibition of VEGF-induced EC tube formation on Matrigel, EC migration, and EC attachment to fibronectin. In addition, it also induced EC apoptosis through a caspase-dependent pathway. Functional mapping identified subregions of LRR5 that inhibited different aspects of angiogenesis. More importantly, the central 12-residue LRR5M specifically inhibited EC tube formation up to 1000 times more potently than LRR5. Whereas the C-terminal 13-residue LRR5C retained the ability to inhibit EC migration, the N-terminal 13-residue LRR5N is as effective as LRR5 in inhibiting EC attachment to fibronectin. Furthermore, both LRR5N and LRR5M induced EC apoptosis, with LRR5M as effective as LRR5. Further mechanistic study indicated that the abilities of LRR5 and LRR5M to inhibit EC tube formation is linked to their inhibition of VEGF-induced FAK phosphorylation at Tyr-397 and subsequent assembly of focal adhesions and actin stress fibers in ECs.
EXPERIMENTAL PROCEDURES
Reagents and Antibodies-Recombinant human VEGF 165 and recombinant human decorin (rhDCN) were purchased from R&D Systems Inc. (Minneapolis, MN). Basic FGF was from Promega (Madison, WI). Purified decorin (DCN) from bovine articular cartilage, gelatin, and Giemsa solution were from Sigma. Falcon cell culture inserts (8.0-m pore size) and Matrigel were from BD Biosciences. Human plasma fibronectin was from Invitrogen. Endothelial culture media CSC were from Cell Systems. Pan-caspase inhibitor Z-VAD-fmk was from Merck. Bovine articular DCN protein concentration (Sigma) was determined by using the Bradford method (Bio-Rad). DCN purity was checked by both native and SDS-PAGE and shown to be more than 95% pure. The endotoxin levels in DCN and rhDCN were determined using ET0200 kit from Sigma.
Peptide Synthesis-Peptides were synthesized by solid phase synthesis using automated peptide synthesizer (PerSeptive Biosystems) adopting Fmoc (N-(9-fluorenyl)methoxycarbonyl) chemistry in-house or procured from a commercial source (SynPep). Peptides were purified by reversed phase high pressure liquid chromatography, freeze-dried, and stored at Ϫ20°C until used.
Cell Culture-Human umbilical vein endothelial cells (HUVECs) were isolated from human umbilical cords and cultured in CSC complete medium at 37°C in a humidified 5% CO 2 atmosphere. All cells used for the experiments were from passages 3-6.
Endothelial Cell Tube Formation Assay-2.5 ϫ 10 4 HUVECs were preincubated with various concentrations of peptides for 30 min before being seeded onto the solidified growth factor reduced Matrigel in a 96-well plate. After incubating in media with or without 15 ng/ml VEGF or bFGF at 37°C for 4 -6 h, cells were fixed, and tube formation was analyzed by light microscopy (ϫ100). Four random fields were chosen in each well, and the total tube length was quantified by using NIH ImageJ 1.32 software.
Cell Migration Assay-Migration assay was performed using Falcon cell culture inserts as described previously with modifications (28) . Briefly, HUVECs were starved overnight, trypsinized, and suspended at a final concentration of 3 ϫ 10 5 cells/ml. Various concentrations of peptides were preincubated with the 2-3 ϫ 10 4 cells for 30 min at 37°C before seeding onto the gelatin-coated cell culture inserts. VEGF (10 ng/ml) was placed into the lower chamber. The assembled cell culture insert chamber was then incubated at 37°C for 8 -12 h. After removing the nonmigrating cells with a cotton swab, migrated cells on the lower surface of the culture inserts were fixed, stained with 0.4% Giemsa, and photographed under a light microscope (ϫ200). Five random fields were chosen in each insert, and the cell number was quantified using the NIH ImageJ 1.32 software.
Proliferation and Cytotoxicity Analyses-Proliferation and cytotoxicity were determined using the nonradioactive EZ4U cell proliferation and cytotoxicity assay kit according to manufacturer's instructions (Biomedica, Vienna, Austria). The method was based on the fact that living cells are capable of reducing less colored tetrazolium salts into intensely colored formazan derivatives. This reduction process requires functional mitochondria, which are inactivated within a few minutes after cell death. In a typical 96-well plate assay, we used around 3000 HUVECs/well, and the absorbance of formazan at 460 nm was represented as mitochondrial activity. For proliferation assays, the cells were incubated in CSC medium plus 2% FBS with or without 10 ng/ml VEGF or bFGF and various concentrations of peptides (1 nM to 100 M) for 48 h, while 6-h peptide incubation was used to measure cytotoxicity.
Cell Attachment Assay-HUVECs were pre-treated with different peptides for 20 min before being plated onto a fibronectin-coated 24-well plate and incubated for 30 min at 37°C. Attached cells were then fixed and stained with Giemsa. The number of cells attached were quantified in five random fields per well. The assay was done in duplicate and repeated three times on separate days.
Apoptosis Assay-Apoptosis was analyzed by morphological detection of chromatin fragmentation as described before (29) . HUVECs grown to 60 -70% confluence in 4-well chamber slides were incubated with peptides for 48 h in 0.5% FBS in the presence or absence of 5-10 ng/ml VEGF. Cells were fixed, stained with Hoechst dye 33258, and observed under a fluorescent microscope (ϫ630). Alternatively, TUNEL staining was performed using the ApoAlert DNA fragmentation assay kit (Clontech). Apoptosis was also quantified using a cell death detection ELISA kit ( Roche   FIG. 2 . LRR5 domain in decorin core protein potently inhibits EC tube formation on Matrigel. A, list of peptides used in this study. B, representative photographs of tube formation assay using growth factor-reduced Matrigel. Each sample was incubated in media containing 0.5% FBS plus 100 M peptide in the presence of 15 ng/ml VEGF. C, quantitation of tube formation inhibition by LRR peptides. LRR5 dose-dependently inhibited VEGF-induced tube formation.
TABLE I Cytotoxicity of LRR5 and its shorter peptides to ECs
The numbers presented are absorbance values at 460 nm using the EZ4U kit, measuring mitochondria enzyme activity. In this assay condition, a decrease in absorbance indicates reduction of viable cells in the sample that represents cytotoxicity. Mean of three experiments are presented. Around 3000 HUVECs/well were used in the 96-well plate assay. Applied Science). Briefly, 20,000 HUVECs/well were seeded onto 0.2% gelatin-coated 24-well plates for 24 h prior to treatment with peptides. Cells were treated with different concentrations of peptides, with or without 10 ng/ml VEGF for 24 h before harvested using trypsin. DNA fragmentation was measured by quantitation of cytosolic oligonucleosomebound DNA according to the manufacturer's instructions. The cytosolic fraction (13,000 ϫ g) of HUVECs treated with peptides in the presence and absence of 10 ng/ml VEGF was used as antigen source in the sandwich ELISA with anti-human histone antibody coated to the plate and a secondary anti-DNA antibody coupled to peroxidase for detection. The effect of peptides in inducing apoptosis was represented as absorbance value at 405 nm. The experiment was also performed in the presence of 10
Solid Phase Binding Assay-Ninety six-well microtiter plates were coated with 100 g/ml collagen I or fibronectin solutions overnight at 4°C. Control wells were coated with 0.1% BSA in phosphate-buffered saline. After rinsing with 0.15 M NaCl, 0.05% (v/v) Tween 20, the wells were preincubated with 0.1% (w/v) BSA for 2 h before incubating with varying concentrations of FITC-labeled peptides for 4 h at room temperature. Fluorescence bound to wells was determined using Spectramax R Gemini XS dual scanning Spectrofluorometer (Molecular Devices, Germany). Saturation graphs were obtained using single site binding, nonlinear regression analysis by Graph Pad Prism 4 (GraphPad Software Inc.). All analyses were done in triplicate.
Western Blot and Immunoprecipitation-Starved HUVECs were treated with 30 M peptides individually for 2 h before exposing to 15 ng/ml VEGF 165 for 30 min. The cells were lysed in cell lysis buffer (Cell Signaling Technology). After adjustment for protein concentration with the Bradford method, 100 g of proteins from each sample were used for Western blot analysis. The blot was probed with primary rabbit anti-FAK antibody (Upstate Biotechnologies, Inc.) and horseradish peroxidase-labeled secondary antibody. The products were visualized by enhanced chemiluminescence reagent (Pierce). On the other hand, 500 g of proteins from the same samples were immunoprecipitated with rabbit anti-FAK antibody at 4°C overnight and probed with primary mouse anti-phospho-FAK (Tyr-397) antibody (Chemicon).
Analysis of Focal Adhesions and Actin Stress Fibers in HUVECs-
Cells were grown to near-confluence on chamber slides. VEGF (10 ng/ml) and peptides (100 M) were added into the wells and incubated for 90 min at 37°C. Cells were fixed, permeabilized, and stained with a mouse monoclonal antibody against paxillin (Upstate Biotechnology, Inc.) and FITC-labeled anti-mouse IgG (Santa Cruz Biotechnology). Slides were observed under confocal microscope (Olympus 1X70). TRITC-conjugated phalloidin (Sigma) was used to stain the actin cytoskeleton, and Hoechst dye 33258 was used to counter stain the nucleus.
Circular Dichroism Spectral Analysis-CD spectra of all peptides were recorded on a Jasco J-810 spectropolarimeter using a 1-mm path length quartz cell at room temperature in 10 mM phosphate buffer, pH 7.0, at 1 mM concentration. The spectra were recorded between 190 and 260 nm with a scan speed of 50 nm/min and were the average of three scans. Base line was subtracted for final representation.
RESULTS
Anti-angiogenic Effect of Decorin and LRR5-There have been conflicting reports regarding the role of decorin in inhibiting angiogenesis when used as a soluble factor. To clarify the role of decorin on EC tube formation, we tested purified decorin from bovine articular cartilage as well as recombinant human decorin expressed in insect cells using HUVEC tube formation assay on Matrigel. Both decorins were found to inhibit VEGF, bFGF, and serum-stimulated HUVEC tube formation on growth factor-reduced Matrigel, with purified bovine articular decorin more potent than recombinant human decorin (Fig. 1,  A and B) . Both decorin preparations inhibited VEGF-induced tube formation more potently than bFGF-induced tube formation. This paper therefore mainly focuses on VEGF-induced angiogenesis in subsequent studies. No endotoxin contamination was found in the decorin preparations (see under "Exper- FIG. 3 . LRR5 inhibits both VEGF and bFGF-induced HUVEC migration. A, LRR5 inhibits EC migration in a dose-dependent manner. VEGF 165 (10 ng/ ml) was used as chemotactic agent. B, bFGF (10 ng/ml) was used as chemoattractant. The % migration in y axis is the mean value from three sets of experiments.
imental Procedures"), confirming that the anti-angiogenic activity is a specific activity of decorin (data not shown).
LRR domains in decorin core protein play important roles in decorin function, and the LRR3-5 region has been shown to be the main region binding collagen I as well as TGF␤ (14, 25) . We set out to test if individual LRR3-5 can inhibit HUVEC tube formation by using a synthetic peptide approach. Fig. 2A lists all the peptides used in this study. Peptide LRR5 effectively inhibited EC tube formation dose-dependently, whereas LRR3 and LRR4 at 100 M only had a mild effect (Fig. 2, B and C) . More importantly, when the LRR5 amino acid sequence was scrambled (LRR5S), the inhibition effect was completely lost. These peptides were not cytotoxic to ECs when tested up to 100 M as shown in Table I . Therefore, LRR5 can specifically inhibit VEGF-induced EC tube formation on Matrigel in a sequence-dependent manner and functions as an angiogenic inhibitor. As angiogenesis involves multiple steps, we tested the LRR peptides for their ability to inhibit EC proliferation and migration. As shown in Fig. 3 , peptide LRR5 potently inhibited VEGF-stimulated EC migration in a dose-dependent as well as sequence-dependent manner with an estimated ED 50 value between 100 nM and 1 M, whereas LRR5S had no such activity. Purified bovine decorin also potently inhibited EC migration at nanomolar concentrations (Fig. 3A) . Both decorin and LRR5 also inhibited bFGF-induced EC migration (Fig. 3B ), but much less effectively when compared with VEGF stimulation. In contrast, neither decorin nor LRR5 had significant inhibitory effect on VEGF-or bFGF-stimulated EC proliferation, with LRR5 having only mild inhibition effect at 100 M (Fig. 4,  A and B) .
Induction of apoptosis in endothelial cells is one of the mechanisms utilized by anti-angiogenic molecules to inhibit angiogenesis. To test whether LRR5 has the ability to induce apoptosis in HUVECs, apoptosis was analyzed by morphological detection of chromatin fragmentation, TUNEL staining, and quantitative ELISA measurement of fragmented DNA in peptide-treated cells. As shown in Fig. 5A , LRR5 specifically induced apoptosis in HUVECs in a concentration-dependent manner. At 100 M, many cells with fragmented chromatins were observed. TUNEL staining also confirmed the morphological observation (Fig. 5B) . ELISA measurement of DNA fragmentation indicated that LRR5 potently induced apoptosis in the presence or absence of VEGF at 100 M, and this inhibition is caspase-dependent as the Pan-caspase inhibitor Z-VAD-fmk effectively abolished its apoptosis inducing activity (Fig. 5B) . Decorin at 100 nM did not induce EC apoptosis (Fig. 5B) .
In summary, decorin and its core protein LRR5 domain were potent angiogenesis inhibitors. LRR5 peptide inhibited angiogenesis through multiple mechanisms, including inhibition of EC tube formation, chemotactic migration, and induction of apoptosis. The anti-angiogenic activity of LRR5 is both sequence-and dose-dependent.
Different Regions of LRR5 Mediate Different Anti-angiogenic Functions-To map the subregions within LRR5 that are responsible for its anti-angiogenic activity and to obtain shorter peptide angiogenic inhibitors, the 26-residue LRR5 was further truncated into three overlapping peptides representing the Nterminal portion (LRR5N, 13 residues), the middle portion (LRR5M, 12 residues), and the C-terminal portion (LRR5C, 13 residues) of LRR5 ( Fig. 2A) . Most interestingly, LRR5M peptide inhibited VEGF-induced HUVEC tube formation on Matrigel much more potently than the LRR5 peptide (Fig. 6A) . Although LRR5 inhibited tube formation in a dose-dependent manner with an ED 50 of around 100 nM, LRR5M completely inhibited tube formation at a 10 nM concentration, and its ED 50 was estimated to be 100 pM, which is up to 1000 times more potent compared with LRR5 (Fig. 6B) . In contrast, peptides LRR5N and LRR5C did not inhibit VEGF-induced EC tube formation effectively. The LRR5 peptides also inhibited bFGFinduced tube formation in a dose-dependent manner, except for LRR5C, which is inactive (Fig. 6C) . Consistent results were observed when experiments were repeated with different batches of HUVECs (data not shown).
When the three shorter peptides were analyzed for their ability to inhibit VEGF-induced HUVEC migration, the 13-residue LRR5C peptide was as potent as LRR5 (Fig. 7A) . Both LRR5 and LRR5C inhibited VEGF-induced EC migration in a dose-dependent manner, with ED 50 values between 100 nM and 1 M. Although some inhibitions were observed with LRR5N, the effects were not dose-dependent, whereas LRR5M was inactive. In comparison, LRR5C was ineffective in inhibiting bFGF-induced EC migration, whereas LRR5M had only a mild inhibitive effect at high concentrations (Fig. 7B) . Consistent with the insignificant inhibition of LRR5 on EC proliferation (Fig. 4, A and B) , LRR5N and LRR5C were only mildly inhibitive to VEGF-stimulated EC proliferation at high concentrations, whereas none of the shorter peptides inhibited bFGFstimulated EC proliferation (Fig. 8, A and B) .
When the three shorter peptides were tested for their ability to induce EC apoptosis, LRR5M is as active as LRR5, and LRR5N is less active (Figs. 5B and 9, A and B) . Similar to LRR5, both shorter peptides induced EC apoptosis in a caspasedependent manner. In contrast, LRR5C lacked the apoptosis induction function.
In summary, the above results indicated that different subregions of LRR5 inhibit different aspects of angiogenesis. Although the middle region inhibited EC tube formation, the
FIG. 4. LRR5 does not inhibit EC proliferation.
A, EC proliferation induced by 10 ng/ml VEGF. LRR5 does not inhibit proliferation up to 10 M concentration, whereas at 100 M there was a mild inhibition. B, EC proliferation induced by 10 ng/ml bFGF. LRR5 does not have any effect on bFGF-stimulated EC proliferation. C-terminal region was responsible for inhibiting EC migration toward VEGF. Both the N-terminal region (LRR5N) and the middle region (LRR5M) were involved in inducing EC apoptosis through the caspase-mediated apoptosis pathway.
LRR5 Inhibited Angiogenesis Not by Interference of EC Attachment to Matrix-Decorin is known to bind many ECM proteins, including fibronectin and collagen as well as growth factors such as TGF␤ (11) (12) (13) (14) (15) . To test if LRR5 and its shorter peptides also bind these proteins, various matrix proteins, including gelatin, collagen I, fibronectin, growth factors (TGF␤1, TGF␤2, VEGF, and bFGF), fibrinogen, and BSA, were immobilized onto nitrocellulose membranes and probed with FITClabeled peptides. All peptides could bind directly to the matrix proteins gelatin, collagen I, and fibronectin but not the other proteins tested (data not shown). Their binding affinities to fibronectin and collagen I were then determined by using a solid phase binding assay. Peptide LRR5 and all the three shorter peptides have a slightly higher binding affinity for collagen I compared with fibronectin, but the binding affinities were generally quite low with K d values in the micromolar or even lower millimolar range (Table II) .
EC attachment and adhesion to ECM are critical for the progression of angiogenesis. Both migration and tube formation are initiated by attachment, and if the peptide acts as an anti-attachment factor, then both cell migration and tube formation could be inhibited. Because LRR5 and its related peptides all bind fibronectin and collagen I, they could interfere with the attachment of EC to the ECM and therefore inhibit angiogenesis. Indeed, when cells were preincubated with the peptides for 30 min before being seeded onto fibronectin-coated 96-well plates, the numbers of cells attached were significantly reduced (Fig. 10 ). Significant inhibitions were observed with LRR5 and LRR5N even at concentration as low as 10 nM, which was comparable with that of purified decorin. In contrast, peptides LRR5M and LRR5C were less effective in this function and only had obvious inhibitory effects at micromolar concentrations. Similarly, these peptides also inhibited EC attachment to collagen I dose-dependently (data not shown). Based on these results, it is obvious that the ability of LRR5 to inhibit EC tube formation and migration is not due to its interference with the attachment of the EC to fibronectin as LRR5N, which is as effective as LRR5 in inhibiting EC attachment to fibronectin, is not effective in inhibiting tube formation or migration.
LRR5 and LRR5M Inhibit VEGF-stimulated FAK Phosphorylation, Localization of Paxillin into Focal Adhesions, and
Formation of Actin Stress Fibers-To understand the differential functions of LRR5M and LRR5C peptides, additional mechanistic studies related to FAK were conducted. FAK is an important component of the focal adhesion complex that attaches cells to the extracellular matrix and is essential for cell migration, adhesion, survival, and cell cycle control (30) . It is a nonreceptor tyrosine kinase, which integrates growth factor and integrin signals to promote cell migration. Proper migration of cells depends on both actin filament dynamics and adhesion complex remodeling. It has been reported that one of the mechanisms of VEGF-stimulated EC migration is by stim- ulating FAK phosphorylation, which activates FAK and initiates the assembly and rearrangements of focal adhesions (31) . Activated FAK then phosphorylates and activates other focal adhesion-associated proteins, including paxillin, which is immediately recruited into focal adhesion complexes. This is followed by an accumulation of actin stress fibers associated with new actin polymerization that interacts with focal adhesion-associated paxillins (32) . FAK is then inactivated by dephosphorylation and is cleaved by cellular proteases, leading to the disassembly of focal adhesions as well as actin filament. During apoptosis, FAK is cleaved by caspases, generating FRNK, a C-terminal fragment of FAK that inhibits FAK function (33) .
As shown in Fig. 11 , both LRR5 and LRR5M suppressed VEGF-stimulated FAK phosphorylation. LRR5M was more effective in inhibiting FAK phosphorylation compared with LRR5, consistent with its more potent activity in inhibiting EC tube formation and apoptosis induction. In contrast, LRR5C, which is very effective at inhibiting EC migration but not active in inhibiting tube formation and induction of apoptosis, did not show any inhibitory effect on FAK phosphorylation. Rather, there is a mild stimulation of FAK phosphorylation by this peptide.
VEGF-induced paxillin recruitment into focal adhesions, an indication of the formation and rearrangement of focal adhesions, was also effectively blocked by both LRR5 and LRR5M. As shown in Fig. 12 , the large number of VEGF-induced patched paxillin staining (indicated by arrowheads) was almost completely abolished upon treatment with LRR5 and LRR5M, with LRR5M being more effective. Purified decorin also inhibited focal adhesion formation at 100 nM. Although peptide LRR5N reduced the formation of focal adhesions to a much lesser extent, LRR5C and LRR5S were inactive (Fig. 12) .
Consistently, LRR5 and LRR5M potently suppressed VEGFinduced actin stress fiber formation as shown by immunofluorescent staining of actin filaments by TRITC-conjugated phalloidin (Fig. 13) . Although LRR5N was less effective, LRR5C was essentially ineffective in this function.
The above three experiments correlated well with each other to reveal that inhibition of EC tube formation on Matrigel and induction of EC apoptosis by peptides LRR5 and LRR5M are linked with their ability to suppress VEGF-induced FAK phosphorylation, paxillin relocation into focal adhesions, and actin stress fiber formation. The more potent LRR5M in inhibiting EC tube formation and induction of EC apoptosis is also more potent in suppressing FAK phosphorylation at Tyr-397.
CD Spectral Studies Revealed a Stable Structure for LRR5 in Solution-
To study the structural basis of the function of the peptide, CD analyses of the peptides were carried out. The CD spectra of peptide LRR5 at 1 mM concentration showed a negative maxima around 212 nm and a negative shoulder around FIG. 7 . Effect of LRR5 shorter peptides on HUVEC migration. A, the anti-migration effect of LRR5N, LRR5M, and LRR5C peptides when stimulated with 10 ng/ml VEGF. LRR5C dose-dependently inhibits VEGF-stimulated EC migration. B, the anti-migration effect of LRR5N, LRR5M, and LRR5C peptides when stimulated with 10 ng/ml bFGF. LRR5C does not inhibit bFGF-stimulated EC migration, whereas peptide LRR5M is effective. The results are mean values from three different experiments.
222 nm, indicating the possibility of a 3 10 helical structure (Fig.  14) . Addition of trifluoroethanol at different ratios from 5 to 80% of trifluoroethanol/water did not reveal any difference in LRR5 CD spectra, indicating the LRR5 peptide has a stable helical structure (34) . Furthermore, a weak bend near 208 nm and two negative minima at 212 and 222 nm could be indicative of this peptide undergoing an inter-conversion of 3 10 and ␤-sheet structure at pH 7.0. A similar absorption pattern was observed for peptide LRR5N with a wide negative minima ranging from 209 to 240 nm and an intense sharp minima at 209 nm, inferring that this peptide also undergoes an interconversion between helix and ␤-sheet or ␤-turn structure. However, the structure of LRR5N is not stable because addition of trifluoroethanol improves the helical shape by eliminating ␤-sheet (data not shown). Scrambled peptide LRR5S showed a strong negative absorption near 210 nm and a weak negative absorption near 222-225 nm, indicating a 3 10 helical structure. The CD spectra of LRR5C and LRR5M both showed a negative absorption at 202-205 nm, which is an indication of type I ␤-turn.
DISCUSSION
Although decorin has been reported to have anti-angiogenic activity under certain circumstances, we showed here for the first time that purified decorin can inhibit VEGF, bFGF, and serum-induced HUVEC tube formation on Matrigel. Purified bovine articular decorin inhibited EC tube formation more potently than recombinant human decorin expressed in insect cells (Fig. 1) . Furthermore, a peptide representing the LRR5 domain of the core protein (26 residues) functions as a potent angiogenesis inhibitor by inhibiting multiple aspects of angiogenesis, including EC tube formation on Matrigel, VEGF, or bFGF-stimulated migration, attachment to fibronectin, as well as inducing EC apoptosis. We further demonstrated that different subregions of LRR5 inhibit different aspects of angiogenesis. The middle region (LRR5M) is responsible for inhibiting EC tube formation. The C-terminal region (LRR5C) specifically inhibits chemotactic EC migration toward the VEGF but has no effect on bFGF-induced EC migration. Both the N-terminal and middle regions are involved in inducing EC apoptosis. On the other hand, the N-terminal region (LRR5N) FIG. 8 . LRR5 shorter peptides do not inhibit EC proliferation. A, EC proliferation stimulated by VEGF at 10 ng/ml. Peptide LRR5N and LRR5C at concentrations 10 M and above have mild inhibition in VEGF-stimulated EC proliferation. B, EC proliferation stimulated by bFGF at 10 ng/ml. None of the peptides had any significant effect on bFGF-stimulated EC proliferation. The results are mean values from three experiments.
is more effective in inhibiting EC attachment to fibronectin. We showed that the ability of LRR5 and LRR5M to inhibit VEGFinduced EC tube formation is linked with their suppression of VEGF-induced FAK activation, assembly of focal adhesions, as well as actin stress fiber formation but not through interference of EC attachment to matrix proteins. A summary of the LRR5 peptides is shown in Table III. VEGF is the most important angiogenic factor that induces EC proliferation, migration, focal adhesion complex formation and reorganization, remodeling of the actin cytoskeleton into stress fibers, as well as tube formation, all necessary components of an angiogenic response. Except proliferation, LRR5 inhibited all aspects of VEGF-induced angiogenesis. The correlation of potent anti-tube formation activity of LRR5 and LRR5M with their ability to inhibit VEGF-induced FAK activation, recruitment of paxillin into focal adhesions, and actin stress fiber formation strongly suggests that the FAK signaling pathways play an important role in VEGF-induced EC tube formation on Matrigel. The more potent anti-tube formation activity of LRR5M correlated with its more potent inhibition of FAK activation.
Although FAK signaling pathways are also involved in VEGF-induced EC migration, LRR5 most likely inhibited EC migration through a FAK-independent signaling pathway as LRR5C, which inhibited EC migration, did not suppress FAK activation. It has been reported recently that integrin-linked kinase (ILK), a signaling protein that interacts with the cytoplasmic domains of integrin, also plays an important role in HUVEC vessel morphogenesis induced by VEGF, and VEGF- FIG. 9 . Different activities of LRR5 subregions in inducing EC apoptosis. A, representative photographs of apoptotic cells after TUNEL staining. The photographs shown here are the effect of peptides in the presence of 10 ng/ml VEGF. LRR5, LRR5N, and LRR5M are effective, and LRR5C is not very effective. B, quantitation of apoptosis using the cell death ELISA measuring fragmented DNA. The experiment is done in the presence or absence of 10 ng/ml VEGF and/or 10 M Z-VAD-fmk, a Pan-caspase inhibitor. LRR5, LRR5N, and LRR5M induce apoptosis even in the presence of VEGF, but this effect is almost completely inhibited by Z-VAD-fmk. All peptides were used at 100 M. induced HUVEC chemotactic migration was suppressed by the inhibition of ILK (35) . ILK also mediates actin filament rearrangements and cell migration and invasion through phosphatidylinositol 3-kinase/Akt/Rac1 signaling (36) . Whether LRR5C also inhibits VEGF-stimulated HUVEC chemotactic migration through inhibition of ILK signaling pathway warrants future investigation. Cell migration involves the dynamic assembly and disassembly of both focal adhesions and actin filaments. Although LRR5C did not inhibit VEGF-induced focal adhesion assembly and actin stress fiber formation, whether it interferes with the disassembly or dynamic changes of them still needs to be investigated. Furthermore, the dynamic cycles of FAK phosphorylation/dephosphorylation are essential for the remodeling of focal adhesions. As LRR5C enhanced FAK Tyr-397 phosphorylation, a possible interference in FAK phosphorylation/dephosphorylation can lead to migration inhibition.
Cell migration can be triggered not only through matrixmediated integrin clustering and FAK activation but also through growth factor/receptor-activated multiple intracellular signaling pathways. In addition to the FAK pathway, many other pathways such as phosphatidylinositol 3-kinase activation, p38 mitogen-activated protein kinase activation, Akt activation, induction of NO release, etc. have also been linked with VEGF-induced EC migration (32) . It is also possible that LRR5C inhibits VEGF-induced EC migration by interfering with one of these pathways.
On the other hand, although LRR5M inhibited VEGF-stimulated FAK phosphorylation, focal adhesion, and actin stress fiber formation in ECs stably cultured on substratum, it did not affect VEGF-stimulated EC migration possibly because VEGF stimulated EC migration through a non-FAK-dependent pathway in the migration assay environment we used. VEGF stimulated focal adhesion and actin stress fiber formation very quickly (within minutes) in ECs stably attached onto the substratum, and the presence of LRR5M is able to inhibit this response. However, in migration assays, ECs are preincubated with the peptides in suspension before plating onto cell culture inserts. The cells then slowly attach to the insert surface and migrate toward the VEGF in the lower chamber. ECs in this migration assay condition may respond differently to LRR5M or VEGF compared with the ECs stably attached onto the substratum.
The signaling pathways that are involved in mediating EC tube formation are not thoroughly understood. As tube formation is a multistep process, including cell-cell adhesion, cellmatrix adhesion, cell fusion, apoptosis, as well as EC differentiation in addition to cell migration, inhibition of FAK activation most likely affected one or more of these processes, excluding cell migration. Our results present a clear link between the ability of LRR5 and LRR5M in inhibiting EC tube formation on Matrigel with their ability to inhibit VEGF-stimulated FAK phosphorylation on Tyr-397, focal adhesion, and actin stress fiber formation in ECs cultured on substratum. Nevertheless, the detailed molecular mechanisms still need further investigation in future work. Consistently, peptides LRR5C and LRR5N, which either enhanced or had no effect on VEGF-induced FAK phosphorylation, have no anti-tube formation activity.
It is known that FAK signaling is involved not only in growth factor and integrin-mediated cell migration but also in cell proliferation, apoptosis, as well as cell adhesion and spreading (37) . It is not clear, however, if inhibition of VEGF-stimulated FAK phosphorylation is involved in LRR5M-induced EC apoptosis as LRR5N, which is also effective in inducing EC apoptosis, has no effect on FAK signaling.
Cell attachment and adhesion to matrix are critical steps in angiogenesis. It is known that cell adhesion and spreading on fibronectin and TSP1 substrates are inhibited by decorin (13, 15). Although LRR5 and LRR5N efficiently interfered with HUVEC attachment to fibronectin at low concentrations, it seems that inhibition of EC attachment to matrix is not a critical mechanism by which LRR5 inhibited EC tube formation. This is because LRR5M potently inhibited EC tube formation at concentrations in which it is not very efficient in inhibiting HUVEC attachment to fibronectin (Figs. 6 and 10) .
The binding affinities of the peptides to collagen I and fibronectin are low, in the low millimolar to micromolar range. By using FITC-labeled peptides, we observed that LRR5 and its related peptides do not enter cells or bind to the cell surface (data not shown), indicating that they most likely function in the extracellular matrix. Although the LRR3-5 region of decorin core protein has been reported to bind TGF␤, a growth factor involved in angiogenesis, LRR5 did not bind this growth factor when tested in binding conditions described in this work (data not shown). Most likely, the anti-angiogenic activity of LRR5 is independent of the ability of decorin to bind TGF␤.
Peptide therapeutics is increasingly making their way into clinical application. The advantage for peptides are their small sizes, simplicity in synthesizing, lack of toxicity, immune reaction to the host system, and viability for chemical modifications (2) . Several anti-angiogenic peptides have been obtained from various domains of endogenous proteins, including the Ex domain of MMP-2, Ig domains of VEGFR1, TAR domains of TSP1, as well as endostatin (5, 28, 38, 39) . This work represents the first report of anti-angiogenic peptides derived from the LRR domains.
It has been reviewed recently that anti-angiogenic peptides tend to have a high incidence of hydrophobic residues and fold as antiparallel ␤-sheets (40) . A potent angiogenesis inhibitor, the 33-amino acid Anginex peptide, has been designed containing a ␤-sheet that is the bioactive conformation (41, 42) . The 26-residue LRR5 peptide also has a ␤-sheet in addition to a stable 3 10 helix structure in solution as indicated by a CD spectrum (Fig. 14) . While this manuscript was in preparation, the crystal structure of the dimeric protein core of decorin was reported (27) , indicating that LRR6 of bovine decorin (equivalent to human LRR5 in this work) contains a 3 10 helix and a ␤-sheet, consistent with our CD results. LRR5 is at the center of the banana-shaped decorin monomer molecule with the 3 10 helix exposed to the external surface and the ␤-sheet at the dimerization interfaces. Among all the LRRs in decorin core protein, only LRR5 has the 3 10 helix structure (27) . In addition, in many bioactive peptides, the presence of ␤-turn is critical for its function (43) . All peptides described here also have a ␤-turn structure that may be important for their biological activities.
In summary, the LRR5 domain of the decorin core protein shows a potent anti-angiogenic effect through inhibiting EC tube formation, migration, attachment to matrix, as well as inducing EC apoptosis. Furthermore, different subregions of LRR5 inhibit different aspects of angiogenesis as follows: LRR5M inhibits tube formation; LRR5C inhibits migration; and LRR5N is most effective in inhibiting EC attachment to matrix. Both LRR5N and LRR5M are involved in inducing EC apoptosis. We further showed that the anti-tube formation activities of LRR5 and LRR5M are linked with their ability to suppress VEGF-stimulated FAK phosphorylation at Tyr-397 as well as focal adhesion and actin stress fiber formation. LRR5M is much more potent in inhibiting tube formation than LRR5. These LRR5 peptides provide new opportunities to dissect the molecular mechanisms involved in angiogenesis and may also act as prototypes for further development of anti-angiogenic drugs.
Addendum-During the course of preparing this manuscript, the crystal structure of the dimeric protein core of decorin was reported (27) . 
